A B S T R A C T In order to study the mechanism of action of a Met-enkephalin (FK 33824) 
INTRODUCTION
FK 33824 is a stable sulfoxidecarbinol analog of methionine enkephalin found to have high affinity for opiate receptors in rat brain (1) and in posterior pituitary gland (2) . A physiological mode of action of the different enkephalin derivatives as putative neurotransmitters or nieuromodulators has been reported (3, 4) . These data support a possible role for enkephalinis in the regulation of the endocrine system, and hormone profiles after treatment with these agents have been outlined in animals and humans (5) (6) (7) (8) . As has been demonstrated by Stubbs et al. (7) and del Pozo et al. (8) , FK 33824 administered to normal men produces decreased plasma concentrations of ACTH anid cortisol. These data, however, do not allow localizaReceived for publication 17 
RESULTS
As shown in Fig. 1(A) , injection of 5 IU LVP 60 min after placebo was followed by a significant (P < 0.05) In the last part of the trial in which a possible direct effect of FK 33824 on the adrenals was studied, synthetic ACTH f81-24 was administered. Fig. 1(C) shows significantly increased cortisol concentrations (P < 0.001, compared with base line 0-60 min) when ACTH was given 60 min after placebo. Cortisol levels rose from 15 min, reaching peak values after 120 min. Administration of FK 33824 at time 0 did not modify the action of ACTH (C), confirming the central mechanism of action of the opiate.
DISCUSSION
It has been reported that plasma cortisol was significantly suppressed below the physiological morning decline in subjects treated with the 'Met-enkephalin derivative FK 33824 (7, 8 (14) , lending support to an effect of FK 33824 at this level. The central mode of action is further evidenced by the failure of FK 33824 to prevent the release of cortisol that follows the administration of exogenous ACTH, and rules out a dual effect at both the pituitary and adrenal level. Furthermore, in vitro data have shown that FK 33824 neither modified the release of corticosteroine by dispersed fasciculata cells of rat adrenals nor interfered with the effect of ACTH on this system when both substances were added simultaneouslI to the medium 2 FK 33824 has been found to elevate plasma growth hormonie and prolactini (6) and reduce ACTH (7) anid vasopressin (15) in normnal volunteers. The effect on growth hormone and prolactin is readily antagonized by naloxone (7, 8) . However, the actions oIn the pituitary-adrenal axis and oIn vasopressin have been found to be resistant to this agent (7, 15 can exhibit endocrine properties partly different from those of the prototype opiate morphine. Thus, Tolis et al. (18) reported that morphine administered to humans resulted in a significant increase in serum prolactin without altering the levels of growth hormone and cortisol, whereas FK 33824 elevates prolactin and growth hormone while decreasing cortisol (7, 8) . It also would be tempting to attribute to Met-enkephalin properties unrelated to opioid mechanisms because in this particular case a direct effect on the pituiitary gland speaks against the role of opiates as intermediary neurotransmiiitters.
